Oligopin® contains French Maritime Pine Bark Extract

Placebo is a mixture of different inert compounds

Metabolic Syndrome

French Maritime Pine Bark Extract - 100mg/day

Oligopin®

Placebo

KGK Science Inc.

A Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

A Randomized, Double-blind, Placebo-controlled, Parallel Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

Change in fasting blood sugar from baseline to day 84 between Oligopin® and placebo.

Change in fasting insulin between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting glucose between Oligopin® and placebo baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting LDL between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting oxLDL between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting HDL between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting total cholesterol between Oligopin® and placebo baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in postprandial glucose between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in BMI between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in waist circumference between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in systolic and diastolic blood pressure between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in heart rate between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in ALT between Oligopin® and placebo pre-baseline and day 84.

Change in AST between Oligopin® and placebo pre-baseline and day 84.

Change in total bilirubin between Oligopin® and placebo pre-baseline and day 84.

Change in creatinine between Oligopin® and placebo pre-baseline and day 84.

Change in sodium ion between Oligopin® and placebo pre-baseline and day 84.

Change in potassium ion between Oligopin® and placebo pre-baseline and day 84.

Change in chloride ion between Oligopin® and placebo pre-baseline and day 84.

Change in eGFR between Oligopin® and placebo pre-baseline and day 84.

Change in WBC count between Oligopin® and placebo pre-baseline and day 84.

Change in neutrophil count between Oligopin® and placebo pre-baseline and day 84.

Change in lymphocyte count between Oligopin® and placebo pre-baseline and day 84.

Change in monocyte count between Oligopin® and placebo pre-baseline and day 84.

Change in eosinophil count between Oligopin® and placebo pre-baseline and day 84.

Change in basophil count between Oligopin® and placebo pre-baseline and day 84.

Change in RBC count between Oligopin® and placebo pre-baseline and day 84.

Change in hemoglobin level between Oligopin® and placebo pre-baseline and day 84.

Change in hematocrit level between Oligopin® and placebo pre-baseline and day 84.

Change in platelet count between Oligopin® and placebo pre-baseline and day 84.

Change in MCV level between Oligopin® and placebo pre-baseline and day 84.

Change in MCH level between Oligopin® and placebo pre-baseline and day 84.

Change in MCHC level between Oligopin® and placebo pre-baseline and day 84.

Change in MPV level between Oligopin® and placebo pre-baseline and day 84.

Change in RDW level between Oligopin® and placebo pre-baseline and day 84.

Les Derives Resiniques et Terpeniques

Overweight

Microtia

Endotoxemia

Insulin Resistance

Non-Alcoholic Fatty Liver Disease

3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks

Camu camu

3 capsules of placebo daily during 12 weeks

Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans

Evaluation of fat accumulation by magnetic resonance imaging (MRI)

Plasma Lipopolysaccharides (LPS) and Lipopolysaccharide Binding Protein (LBP)

Measure short chain fatty acids in the feces

Evaluation of gastrointestinal symptoms using a standardized questionnaire (the gastrointestinal symptom rating scale (GSRS))

Evaluation of stool consistency using a standardized questionnaire (Bristol stool chart)

Evaluation of plasma glucose using a 3-hour oral glucose tolerance test

Evaluation of insulin concentration using a 3-hour oral glucose tolerance test

Evaluation of c-peptide concentration using a 3-hour oral glucose tolerance test

Evaluation of plasma triglycerides (TG), Total cholesterol, LDL, HDL, Apolipoprotein B and free fatty acids

Evaluation of BMI (measured with weight change and height throughout the protocol)

Evaluation of body composition by osteodensitometry

Evaluation of plasma high sensitive C-Reactive Protein (hs-CRP)

Evaluation of aspartate transaminase and alanine aminotransferase (AST and ALT)

Transcriptomic analyses to investigate underlying mechanisms of action

Evaluation of camu-camu derived metabolites, short chain fatty acids, branched chain fatty acids, bile acids, phenolic compounds

Evaluation of metabolome: camu-camu derived metabolites, short chain fatty acids, branched chain fatty acids, bile acids, phenolic compounds

Evaluation of systolic and diastolic blood pressure

André Marette

Professor

Laval University

Consumption for eight weeks of 50 grams of chocolate with 70% cocoa solids equivalent to not less than 430 mg of cocoa polyphenols at each dose.

Consumption for eight weeks of 50 grams of chocolate free of cocoa solids as placebo.

Consumption for 8 weeks of 50 grams of chocolate per day with 70% cocoa solids.

Cacao 70%

White chocolate

Cacao Consumption in Patients With Insulin Resistance

Controlled Clinical Trial of the Effect of Cocoa Consumption in Patients With Insulin Resistance

Universidad de Antioquia

Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)

Participants will consume 100 ml of pure Aronia juice per day for 28 days

Participants will consume 100 ml of Aronia juice-based beverage per day for 28 days.

Participants will consume 100 ml of Placebo beverage per day for 28 days

Hypertension

Pure Aronia juice with appx. polyphenols content of 1000 mg gallic acid equivalents/100ml

Pure Aronia juice

Aronia juice-based beverage with appx. polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.

Aronia juice-based beverage

A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions

Placebo beverage

Centre of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade

The Effects of Aronia Juice Polyphenols on Cardiovascular Disease Risk

Investigation of Beneficial Effects of Aronia Juice (Aronia Melanocarpa) and Dietary Polyphenols on the Activity of Thrombocytes as Well as Other Risk Factors Causing Cardio-vascular Diseases

Percentage of P-selectin and GPIIbIIIa positive platelets evaluated in total number of 20000 platelets, percentage of platelet-monocyte aggregates in 1000 monocytes and percentage of platelet-neutrophil aggregates in total 20000 neutrophils, all by flow cytometry, in non-treated blood samples and after ex vivo treatment of the whole blood with adenosine-diphosphate (0.5 μM and 20 μM)

In 12h-fasting and 2h postprandial serum samples analysed by biochemical analyser.

Total cholesterol, LDL-cholesterol and HDL-cholesterol levels in 12h-fasting serum samples analysed by biochemical analyser

In 12h-fasting and 2h postprandial serum samples analysed by biochemical analyser

Mean of 3 x 2 consecutive office measurements performed within 30 min at each time point with professional OMRON device

Body weight will be measured by bio-impedance scale

Waist circumference will be measured by professional tape, according to the guidelines

Body mass index will be calculated based on values obtained as body weight in kilograms divided by height in meters squared.

Body fat as percentage of total weight measured by bio-impedance instrument

Body water as percentage of total weight measured by bio-impedance instrument

Percentages of total body muscle mass in kilograms will be measured by bio-impedance instrument

Aspartate transferase, alanine transferase , direct bilirubin, total bilirubin, gamma-glutamyl transferase , lactate dehydrogenase levels in 12h-fasting serum samples analysed by biochemical analyser

Urea and creatinine levels in 12h-fasting serum samples analysed by biochemical analyser

In 12h-fasting serum samples analysed by biochemical analyser

Both caloric intake and intake of polyphenols will be assessed by standardized food-frequency questionnaire and 24-recall at baseline and after each wash—out period, based on data from Serbian Food Composition database. The agreements between two methods will also be assessed.

procyanidin/rasvumus

A Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans

Cacao Consumption in Patients With Insulin Resistance

The Effects of Aronia Juice Polyphenols on Cardiovascular Disease Risk

Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus